UNITED STATES SECURITIES AND EXCHANGE COMMISSION ~~Washington~~WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 October 4, 2013 Date of Report (Date of earliest event reported) First China Pharmaceutical Group, Inc. (Exact Name of Registrant as Specified in Charter)

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THESECURITIES EXCHANGE ACT OF 1934

September 3, 2013 Date of Report (Date of earliest event reported)

FIRST CHINA PHARMACEUTICAL GROUP, INC. (Exact Name of Registrant as Specified in Charter)

Nevada	000-54076	74-3232809
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

Number 504, West Ren Min Road, Kunming City, Yunnan Province People’s Republic of China, 650000 (Address of Principal Executive Offices) 852-2138-1668 (Registrant’s telephone number, including area code) _____________________________________________________ (Former Name or Former Address, if Changed Since Last Report.)

852-2138-1668 (Registrant’s telephone number, including area code) (Former Name or Former Address, if Changed Since Last Report.) \

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

SECTION 4 - MATTERS RELATED TO ACCOUNTANTS AND FINANCIAL STATEMENTS

Item 4.01. Changes in Registrant’s Certifying Accountant.

~~Effective September 3, 2013, EFP Rotenberg LLP~~ (~~“EFP”~~b) ~~resigned~~ asNew ~~the~~ independent registered public accounting firm ~~of First China Pharmaceutical Group, Inc. (the “Company”). The Company’s Board of Directors informed EFP that it would not accept their resignation.~~

~~EFP~~On ~~maintains~~October ~~that~~4, ~~it resigned due to an outstanding amount of $40~~2013,~~000~~ ~~relating~~the toAudit ~~its~~Committee ~~audit~~ of the ~~Company’s~~Board ~~financial statements for the~~of ~~fiscal~~Directors ~~year~~of ~~ended~~First ~~December~~China 31Pharmaceutical Group, ~~2012~~Inc. (the “~~2012 Audit~~Company”). ~~However, the Company~~engaged ~~previously~~Marcum onBernstein ~~August~~& 6,Pinchuk ~~2013~~LLP ~~offered to pay~~ (the ~~$40,000~~“New toAccountant”) ~~EFP~~as inits ~~advance of~~independent ~~completion~~registered ofpublic ~~the~~accounting ~~2012~~firm ~~Audit if a memorandum of understanding was signed and sent~~ to audit the Company.’s ~~EFP~~financial ~~ignored this communication as well as other~~statements ~~communications~~for ~~from~~ the Company~~. The Company also requested EFP~~’s ~~reassurance~~current ~~in writing~~fiscal ~~that~~year ifending ~~all~~December ~~payments~~31, ~~are~~2013 ~~made,~~and the ~~2012~~fiscal year ~~Audit~~ended ~~and~~December ~~related~~31, ~~filings will be made~~2012. The ~~Company~~New ~~made~~Accountant ~~this~~will ~~request~~now ~~because~~complete ofits ~~EFP’s unresponsive behavior to~~onsite ~~the~~due ~~Company’s~~diligence ~~attempts~~before toformally ~~finalize~~accepting the ~~memorandum of understanding~~engagement. ~~EFP~~The ~~has~~due ~~not~~diligence is ~~provided~~expected ~~the~~to ~~written~~be ~~confirmation~~completed ~~requested~~before by the ~~Company~~end ~~or responded to the Company’s efforts to negotiate a memorandum~~ of ~~understanding~~October 2013.

~~The~~During ~~reports~~the Company’s two most recent fiscal years and through the interim period preceding the engagement of ~~EFP~~the ~~regarding~~New Accountant, the Company (a) has not engaged the New Accountant as either the principal accountant to audit the Company’s financial statements, or as an independent accountant to ~~for~~audit a significant subsidiary of the ~~nine~~Company ~~months~~and ~~ended~~on ~~December~~whom ~~31,~~the ~~2011~~principal accountant ~~did~~is expected to express reliance in its report; and (b) has not consulted ~~contain~~with ~~any~~the ~~adverse~~New ~~opinion~~Accountant regarding (i) the application of accounting principles to a specific transaction, either completed or ~~disclaimer~~proposed, or the type of audit opinion ~~and~~that ~~were~~might ~~not~~be ~~qualified~~rendered oron ~~modified~~the asCompany’s tofinancial ~~uncertainty~~statements, ~~audit~~and ~~scope~~no written report or ~~accounting~~oral ~~principles.~~advice ~~EFP~~was ~~did~~provided ~~not~~to ~~issue~~the aCompany ~~report~~by ~~regarding~~the New Accountant concluding there was an important factor to be considered by the Company’s in reaching a decision as to an accounting, auditing or financial reporting ~~statements~~issue; ~~for~~or (ii) any matter that was either the ~~fiscal~~subject ~~year~~of ~~ended~~a disagreement, ~~December~~as 31that term is defined in Item 304(a)(1)(iv) of Regulation S-K or a reportable event, ~~2012~~as that term is described in Item 304(a)(1)(v) of Regulation S-K.

~~During~~SIGNATURES the nine months ended December 31, 2011, and during the period from January 16, 2012 through September 3, 2013, the date of dismissal, (i) there were no disagreements with EFP on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedures, which disagreements, if not resolved to the satisfaction of EFP would have caused it to make reference to such disagreement in its reports; and (ii) there were no reportable events as defined in Item 304(a)(1)(v) of Regulation S-K.

~~The~~ Pursuant ~~Company~~to ~~has~~the ~~provided~~requirements ~~EFP with a copy~~ of ~~the foregoing~~ ~~disclosures and requested that EFP furnish~~ the ~~Company~~Securities ~~with~~Exchange aAct ~~letter~~of ~~addressed to the SEC stating whether or not it agrees with the above statements~~1934, ~~and~~as ~~if not~~amended, ~~stating~~ the ~~respects~~registrant inhas ~~which~~duly itcaused this ~~does~~report ~~not~~to ~~agree.~~be Asigned ~~copy~~on ofits ~~such~~behalf ~~letter~~by ~~is filed~~the asundersigned ~~Exhibit~~hereunto 16duly authorized.1 ~~to this Current Report on Form 8-K.~~

SECTION 9 - FINANCIAL STATEMENTS AND EXHIBITS

	First China Pharmaceutical Group, Inc.

Dated: October 4, 2013	By:	/s/ Zhen Jiang Wang
		Zhen Jiang Wang
		Chief Executive Officer

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

	Exhibit
	Number	Description
	16.1	Letter from EFP Rotenberg LLP, dated September 10, 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

First China Pharmaceutical Group, Inc.

Dated: September 13, 2013	By:	/s/ Zhen Jiang Wang
		Zhen Jiang Wang
		Chief Executive Officer

Filing Compare · FIRST CHINA PHARMACEUTICAL GROUP, INC.